文献速递血脂与心血管预防

降甘油三酯与心血管风险降低的关联:多项降脂治疗类别的系统综述与Meta回归分析

Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials.
PubMed 文献 · Circulation · 2019-09-18

结果显示,校正LDL-C降低后,甘油三酯每降低1 mmol/L,主要血管事件风险比为0.84(95%CI 0.75-0.94;P=0.0026),但剔除REDUCE-IT试验后相关性减弱(RR 0.91,95%CI 0.81-1.006;P=0.06)。

要点

  • 甘油三酯降低与主要血管事件风险降低相关,但效应小于LDL-C降低。
  • REDUCE-IT试验是显著离群值,剔除后甘油三酯降低的获益不再显著。
  • 海洋来源ω-3脂肪酸中,二十碳五烯酸每增加1 g/d与主要血管事件相对风险降低7%相关。

核心结论

  • 在随机对照试验中,甘油三酯降低与主要血管事件风险降低相关,即使校正LDL-C降低后仍存在,但效应小于LDL-C且剔除REDUCE-IT后减弱。
  • 海洋来源ω-3脂肪酸(尤其高剂量二十碳五烯酸)的获益似乎超过其降脂效应。

研究设计与样本

  • 非他汀治疗类别包括贝特类、烟酸和海洋来源ω-3脂肪酸。

主要发现

  • 非高密度脂蛋白胆固醇每降低1 mmol/L,主要血管事件风险比0.79(95%CI 0.76-0.82;P<0.0001;每40 mg/dL为0.78)。
  • 多变量Meta回归模型中,LDL-C每降低1 mmol/L的风险比0.80(95%CI 0.76-0.85;P<0.0001;每40 mg/dL为0.79),甘油三酯每降低1 mmol/L的风险比0.84(95%CI 0.75-0.94;P=0.0026;每40 mg/dL为0.92)。
  • 剔除REDUCE-IT后,LDL-C每降低1 mmol/L的风险比0.79(95%CI 0.76-0.83;P<0.0001;每40 mg/dL为0.78),甘油三酯每降低1 mmol/L的风险比0.91(95%CI 0.81-1.006;P=0.06;每40 mg/dL为0.96)。
  • 二十碳五烯酸每1 g/d与主要血管事件相对风险降低7%相关(RR 0.93,95%CI 0.91-0.95;P<0.0001)。
  • 二十二碳六烯酸剂量与主要血管事件相对风险降低无显著关联(RR 0.96,95%CI 0.89-1.03)。

关键数值与推荐

  • 非高密度脂蛋白胆固醇每降低1 mmol/L,主要血管事件RR 0.79(95%CI 0.76-0.82)。
  • 校正LDL-C后,甘油三酯每降低1 mmol/L,主要血管事件RR 0.84(95%CI 0.75-0.94;P=0.0026)。
  • 二十碳五烯酸每1 g/d,主要血管事件RR 0.93(95%CI 0.91-0.95;P<0.0001)。

临床怎么用

  • 甘油三酯降低可作为心血管风险管理的辅助目标,但LDL-C降低仍是首要靶点。
  • 高剂量二十碳五烯酸可能带来超出降脂效应的心血管获益,但需考虑REDUCE-IT试验的离群影响。
  • 贝特类和烟酸的降甘油三酯作用对心血管事件的影响需结合具体药物和人群评估。

局限性

  • 研究为试验水平Meta回归分析,存在生态学偏倚风险。
  • REDUCE-IT试验为显著离群值,剔除后甘油三酯降低的获益不再显著,提示结果受单一试验影响较大。
  • 未纳入个体水平数据,无法评估患者层面异质性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Randomized trials of therapies that primarily lowered triglycerides have not consistently shown reductions in cardiovascular events. METHODS: We performed a systematic review and trial-level meta-regression analysis of 3 classes of lipid-lowering therapies that reduce triglycerides to a greater extent than they do low-density lipoprotein cholesterol (LDL-C): fibrates, niacin, and marine-derived omega-3 fatty acids. Key inclusion criteria were a randomized controlled trial that reported major vascular events. We also incorporated data from a previous meta-regression of 25 statin trials. The main outcome measure was the risk ratio (RR) for major vascular events associated with absolute reductions in lipid parameters. RESULTS: A total of 197 270 participants from 24 trials of nonstatin therapy with 25 218 major vascular events and 177 088 participants from 25 trials of statin therapy with 20 962 major vascular events were included, for a total of 374 358 patients and 46 180 major cardiovascular events. Starting with non-high-density lipoprotein cholesterol, a surrogate for very-low-density lipoproteins and low-density lipoproteins, the RR per 1-mmol/L reduction in non-high-density lipoprotein cholesterol was 0.79 (95% CI, 0.76-0.82; P<0.0001; 0.78 per 40 mg/dL). In a multivariable meta-regression model that included terms for both LDL-C and triglyceride (surrogates for low-density lipoproteins and very-low-density lipoproteins, respectively), the RR was 0.80 (95% CI, 0.76-0.85; P<0.0001) per 1-mmol/L (0.79 per 40 mg/dL) reduction in LDL-C and 0.84 (95% CI, 0.75-0.94; P=0.0026) per 1-mmol/L (0.92 per 40 mg/dL) reduction in triglycerides. REDUCE-IT (Reduction of Cardiovascular Events With Icosapent Ethyl-Intervention Trial) was a significant outlier and strongly influential trial in the meta-regression. When removed, the RRs became 0.79 (95% CI, 0.76-0.83; P<0.0001) per 1-mmol/L (0.78 per 40 mg/dL) reduction in LDL-C and 0.91 (95% CI, 0.81-1.006; P=0.06) per 1-mmol/L (0.96 per 40 mg/dL) reduction in triglycerides. In regard to omega-3 dose, each 1 g/d eicosapentaenoic acid administered was associated with a 7% relative risk reduction in major vascular events (RR, 0.93 [95% CI, 0.91-0.95]; P<0.0001), whereas there was no significant association between the dose of docosahexaenoic acid and the relative risk reduction in major vascular events (RR 0.96 [95% CI, 0.89-1.03]). CONCLUSIONS: In randomized controlled trials, triglyceride lowering is associated with a lower risk of major vascular events, even after adjustment for LDL-C lowering, although the effect is less than that for LDL-C and attenuated when REDUCE-IT is excluded. Furthermore, the benefits of marine-derived omega-3 fatty acids, particularly high-dose eicosapentaenoic acid, appear to exceed their lipid-lowering effects.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Marston NA, Giugliano RP, Im K, et al. Association Between Triglyceride Lowering and Reduction of Cardiovascular Risk Across Multiple Lipid-Lowering Therapeutic Classes: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials. Circulation. 2019. PMID: 31530008. doi:10.1161/CIRCULATIONAHA.119.041998

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。